Arena Pharmaceuticals Inc. Daily Stock Analysis

Daily Stock Analysis, ARNA, Arena Pharmaceuticals Inc, priceseries

Arena Pharmaceuticals Inc. Daily Stock Analysis
Stock Information
Open
94.00
Close
93.62
High
94.50
Low
93.53
Previous Close
93.92
Daily Price Gain
-0.30
YTD High
95.32
YTD High Date
Mar 1, 2022
YTD Low
89.03
YTD Low Date
Jan 25, 2022
YTD Price Change
0.43
YTD Gain
0.46%
52 Week High
95.32
52 Week High Date
Mar 1, 2022
52 Week Low
45.50
52 Week Low Date
Aug 19, 2021
52 Week Price Change
22.16
52 Week Gain
31.01%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jun 26. 2017
15.08
Jul 27. 2017
23.60
22 Trading Days
56.50%
Link
LONG
Sep 6. 2017
23.02
Sep 26. 2017
24.75
14 Trading Days
7.53%
Link
LONG
Nov 21. 2017
27.23
Dec 14. 2017
29.98
16 Trading Days
10.10%
Link
LONG
Dec 21. 2017
31.60
Jan 11. 2018
36.45
13 Trading Days
15.36%
Link
LONG
Apr 17. 2018
37.03
May 9. 2018
40.55
16 Trading Days
9.51%
Link
LONG
Aug 28. 2018
37.84
Oct 4. 2018
43.55
26 Trading Days
15.10%
Link
LONG
Jan 29. 2019
43.95
Feb 27. 2019
48.90
20 Trading Days
11.25%
Link
LONG
Jun 27. 2019
57.92
Jul 25. 2019
61.88
19 Trading Days
6.84%
Link
LONG
Jan 31. 2020
45.69
Feb 13. 2020
48.92
9 Trading Days
7.08%
Link
LONG
Apr 2. 2020
43.99
Apr 21. 2020
47.90
12 Trading Days
8.90%
Link
LONG
Oct 2. 2020
74.98
Oct 16. 2020
80.95
10 Trading Days
7.96%
Link
LONG
Jun 9. 2021
62.28
Jun 30. 2021
68.78
15 Trading Days
10.43%
Link
LONG
Aug 31. 2021
52.92
Sep 14. 2021
57.88
9 Trading Days
9.37%
Link
Company Information
Stock Symbol
ARNA
Exchange
NasdaqGS
Company URL
http://www.arenapharm.com
Company Phone
858-453-7200
CEO
Amit D. Munshi
Headquarters
California
Business Address
6154 NANCY RIDGE DRIVE, SAN DIEGO, CA 92121
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001080709
About

Arena Pharmaceuticals, Inc. is a biopharmaceutical company engages in the discovery, development, and commercialization of novel drugs that target G protien-coupled receptors. It offers a range of drugs for treatment in the field of cardiovascular, central nervous system, inflammatory, and metabolic diseases. The company was founded by Dominic P. Behan and Jack Lief on April 14, 1997 and is headquartered in San Diego, CA.

Description

Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel small molecule drugs for various therapeutic areas in the United States and Switzerland. The company's proprietary investigational clinical programs include etrasimod (APD334), which is in Phase IIb evaluation for ulcerative colitis, as well as is in Phase IIa evaluation for dermatologic extraintestinal manifestations in inflammatory bowel disease, pyoderma gangrenosum, and primary biliary cholangitis; ralinepag that is in Phase IIb evaluation to treat pulmonary arterial hypertension; and APD371, which is in Phase IIa evaluation for the treatment of pain associated with Crohn's disease. It has collaboration agreements with Eisai Inc.; Eisai Co., Ltd.; Axovant Sciences Ltd.; and Boehringer Ingelheim International GmbH. Arena Pharmaceuticals, Inc. was founded in 1997 and is based in San Diego, California.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading